First Trust Advisors LP Has $35.28 Million Holdings in BioNTech SE Sponsored ADR $BNTX

First Trust Advisors LP grew its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 4.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 331,360 shares of the company’s stock after buying an additional 14,425 shares during the quarter. First Trust Advisors LP owned approximately 0.14% of BioNTech worth $35,280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in BioNTech by 94.6% during the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock valued at $108,859,000 after acquiring an additional 581,173 shares in the last quarter. Invesco Ltd. increased its stake in shares of BioNTech by 643.7% during the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock worth $58,747,000 after purchasing an additional 558,389 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of BioNTech by 58.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after purchasing an additional 410,351 shares during the last quarter. Millennium Management LLC lifted its stake in shares of BioNTech by 252.5% in the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock valued at $49,625,000 after purchasing an additional 390,360 shares during the last quarter. Finally, Aberdeen Group plc boosted its holdings in BioNTech by 87.2% in the second quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after purchasing an additional 336,260 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of analyst reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $134.00 price target on shares of BioNTech in a research report on Monday, November 3rd. Bank of America reduced their target price on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a report on Tuesday, November 25th. HC Wainwright lifted their price target on shares of BioNTech from $136.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Finally, UBS Group raised shares of BioNTech to a “hold” rating in a report on Thursday, December 4th. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $136.42.

BioNTech Stock Performance

NASDAQ:BNTX opened at $95.85 on Wednesday. The firm’s 50-day moving average is $102.78 and its 200-day moving average is $105.15. The company has a market cap of $21.58 billion, a price-to-earnings ratio of -36.44 and a beta of 1.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $129.27.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The firm had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same period last year, the business earned $0.81 earnings per share. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. Equities research analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.